Abbreviated Dual Antiplatelet Therapy in Patients With High Bleeding Risk Undergoing PCI of Bifurcation Lesions: A Prespecified Substudy of the MASTER DAPT Trial

Heart, Artery and Coronary Diseases

Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis

JAMA Cardiol

Zito A, Landi A, Bhatt DL, Chen SL, De Luca G, Franzone A, Gwon HC, Kang J, Hahn JY, Hong SJ, Jang Y, Kim BK, Kim HS, Kimura T, Mehran R, Park KW, Steg PG, Stone GW, Vranckx P, Windecker S, Valgimigli M

doi: 10.1001/jamacardio.2026.1922

Heart, Artery and Coronary Diseases

Biodegradable polymer sirolimus-eluting or durable polymer zotarolimus-eluting stents in high bleeding-risk patients with acute coronary syndrome: the BIOFLOW-DAPT randomized trial

Eur Heart J Acute Cardiovasc Care

Mankerious N, Hemetsberger R, Wlodarczak A, Merkely B, Kelbæk H, Cayla G, Legutko J, Galli S, Godin M, Toth GG, Lhermusier T, Saad M, Honton B, Sanguineti F, Dietrich PL, Frank D, Stammen F, Ferdinande B, Silvain J, Capodanno D, Nef H, Richardt G, Toelg R, Valgimigli M

doi: 10.1093/ehjacc/zuag089

Atrial FibrillationHeart, Artery and Coronary Diseases

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial

Lancet

Sotomi Y, Kozuma K, Higuchi Y, Nakazawa G, Morino Y, Ando K, Ako J, Tanabe K, Muramatsu T, Kobayashi K, Ichibori Y, Ishihara T, Hirooka K, Suwa S, Warisawa T, Naganuma T, Kikuchi A, Shutta R, Okamoto N, Tanabe Y, Okamura A, Kashiwabara K, Hikoso S, Sakata Y, OPTIMA-AF Investigators

doi: 10.1016/S0140-6736(26)00665-3

Myocardial Infarction

Clinical Outcomes of Complete Revascularization in Acute Myocardial Infarction Patients With High Bleeding Risk and Multivessel Disease

J Am Heart Assoc

Kim O, Joh HS, Kim HK, Kim JH, Hong YJ, Ahn Y, Jeong MH, Hur SH, Kim DI, Chang K, Park HS, Bae JW, Jeong JO, Park YH, Yun KH, Yoon CH, Kim Y, Hwang JY, Kim HS, Kwon W, Shin D, Choi KH, Park TK, Yang JH, Song YB, Hahn JY, Choi SH, Gwon HC, Lee SH, Lee JM, KAMIR Investigators

doi: 10.1161/JAHA.125.042507

Cardiovascular Risk and Diseases

Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial

Front Endocrinol (Lausanne)

Jiang W, Wang J, Li J, Li Y, Zhang Y, Xu J, Zhang J, Gao Z, Cheng J, Yang J, Chang B

doi: 10.3389/fendo.2026.1768816

Cardiovascular Risk and Diseases

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial

JAMA Cardiol

Mulvagh SL, Inzucchi SE, Marx N, Poulter NR, Deanfield JE, Pop-Busui R, Emerson SS, Mann JFE, Engelmann MDM, Hovingh GK, Mandavya K, Davicevic-Elez Z, Jeppesen OK, Lorenzatti A, Oguz A, Mankovsky B, Deerochanawong C, Gorgojo-Martinez JJ, Ji L, Bain SC, McGuire DK, Buse JB, SOUL Study Group

doi: 10.1001/jamacardio.2026.0245

Heart, Artery and Coronary DiseasesTherapy and Intervention

Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial

Lancet

Delewi R, Aarts HM, Broeze GM, Hemelrijk KI, van Ginkel DJ, Versteeg GAA, Grundeken MJ, Claessen BEPM, Tonino PAL, Schotborgh CE, Meuwissen M, van Houwelingen GK, Wykrzykowska JJ, Amoroso G, Vossenberg TN, Vriesendorp PA, van Royen N, Ten Berg JM, Tijssen JGP, Voskuil M, PRO-TAVI trial investigators

doi: 10.1016/S0140-6736(26)00308-9

Heart, Artery and Coronary DiseasesTherapy and Intervention

Oral Anticoagulation With or Without Antiplatelet Therapy in Chronic Coronary Syndrome: A Meta-Analysis of Randomized Trials

JACC Cardiovasc Interv

Galli M, Vinciguerra M, Laudani C, Occhipinti G, D'Amario D, Iaconelli A, Franchi F, Greco E, Frati G, Sciarretta S, Capodanno D, Gorog DA, Lopes RD, Gibson CM, Mehran R, Angiolillo DJ

doi: 10.1016/j.jcin.2026.03.020

Heart, Artery and Coronary DiseasesTherapy and Intervention

IVUS, OCT, or Angiography as Guidance for PCI in Complex Coronary Artery Lesions: Network Meta-Analysis of Randomized Controlled Trials

JACC Cardiovasc Interv

Carvalho PEP, Antunes VLJ, Bittar de Pontes V, Gomes WF, Polachini Assunes Goncalves B, Caixeta A, Strepkos D, Alexandrou M, Mutlu D, Gibson CM, Stone GW, Bhatt DL, Windecker S, Patel MR, Angiolillo D, Mehran R, Valgimigli M, Costa MA, Sandoval Y, Brilakis ES, Lopes RD, Nascimento BR

doi: 10.1016/j.jcin.2025.11.021

Related content

Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis

Biodegradable polymer sirolimus-eluting or durable polymer zotarolimus-eluting stents in high bleeding-risk patients with acute coronary syndrome: the BIOFLOW-DAPT randomized trial

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial

Clinical Outcomes of Complete Revascularization in Acute Myocardial Infarction Patients With High Bleeding Risk and Multivessel Disease

Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial

Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial

Oral Anticoagulation With or Without Antiplatelet Therapy in Chronic Coronary Syndrome: A Meta-Analysis of Randomized Trials

IVUS, OCT, or Angiography as Guidance for PCI in Complex Coronary Artery Lesions: Network Meta-Analysis of Randomized Controlled Trials